验证数据展示
经过测试的应用
Positive IF/ICC detected in | U2OS cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL488-84793-5 targets RNF2 in IF/ICC applications and shows reactivity with human samples.
经测试应用 | IF/ICC Application Description |
经测试反应性 | human |
免疫原 | RNF2 fusion protein Ag8900 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Recombinant |
产品类型 | Antibody |
全称 | ring finger protein 2 |
别名 | 242181G7, BAP 1, BAP1, DING, E3 ubiquitin-protein ligase RING2 |
计算分子量 | 336 aa, 38 kDa |
观测分子量 | 38 kDa |
GenBank蛋白编号 | BC012583 |
基因名称 | RNF2 |
Gene ID (NCBI) | 6045 |
偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
最大激发/发射波长 | 493 nm / 522 nm |
形式 | Liquid |
纯化方式 | Protein A purification |
UNIPROT ID | Q99496 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
RNF2 (also known as ding, Ring1B or Ring2) is a member of the Ring finger protein family, which functions as E3 ubiquitin ligase for monoubiquitination of histone H2A at lysine 119 (H2AK119ub). Many studies have demonstrated that overexpressed RNF2 was involved in the pathological progression of multiple cancers and has an impact on their clinical features. For instance, the upregulated expression level of RNF2 is positively correlated with the occurrence and progression of hepatocellular carcinoma, melanoma, prostate cancer, breast cancer, pancreatic cancer, gastric cancer, and bladder urothelial carcinoma, as well as with the radioresistance of lung cancer and chemoresistance of ovarian cancer (PMID: 33400276). The molecular weight of RNF2 is 38 kDa.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 RNF2 antibody CL488-84793-5 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |